Twist Bioscience (NASDAQ:TWST) Price Target Cut to $37.00 by Analysts at Barclays

Twist Bioscience (NASDAQ:TWST) had its price objective decreased by Barclays from $40.00 to $37.00 in a research note issued to investors on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

TWST has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Twist Bioscience in a research note on Thursday. Stephens started coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target on the stock. Evercore ISI reduced their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Finally, Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Ten research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.50.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $26.46 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -20.20 and a beta of 2.43. Twist Bioscience has a one year low of $23.30 and a one year high of $55.33. The company has a 50 day moving average price of $29.74 and a 200 day moving average price of $31.21.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The company had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.62%. Twist Bioscience has set its Q1 2026 guidance at EPS. FY 2026 guidance at EPS. Sell-side analysts anticipate that Twist Bioscience will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 5,517 shares of the firm’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $173,454.48. Following the completion of the sale, the chief financial officer directly owned 111,008 shares in the company, valued at $3,490,091.52. This trade represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 4,887 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $156,774.96. Following the completion of the transaction, the chief executive officer owned 733,922 shares in the company, valued at approximately $23,544,217.76. This trade represents a 0.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 122,865 shares of company stock valued at $3,879,926. 3.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. increased its stake in shares of Twist Bioscience by 37.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 497,138 shares of the company’s stock worth $13,989,000 after buying an additional 134,929 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Twist Bioscience by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,485 shares of the company’s stock worth $553,000 after acquiring an additional 675 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter worth about $363,000. Sherbrooke Park Advisers LLC acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $242,000. Finally, Quarry LP bought a new position in shares of Twist Bioscience during the third quarter worth about $28,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.